Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
A Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA Versus Ferumoxytol Vascular Enhanced MRI (VE-MRI) for the Detection of Clinically Significant Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in Subjects With Peripheral Arterial Disease Scheduled for Digital Subtraction Angiography (DSA)
Sponsor: AMAG Pharmaceuticals, Inc.
Listed as NCT00707876, this PHASE2 trial focuses on Peripheral Arterial Disease (PAD) and remains ongoing. Sponsored by AMAG Pharmaceuticals, Inc., it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 4 earlier versions
-
Oct 2018 — May 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AMAG Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .